Mesoporous silica nanoparticles-assisted ruthenium(II) complexes for live cell staining

Wen, Jia; Yan, Hui; Xia, Pengyi; Xu, Yongqian; Li, Hongjuan; Sun, Shiguo

doi:10.1007/s11426-016-0409-4

Cited by 26 publications

(17 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, some other more advanced cytotoxic systems based on silica have also been reported. [44][45][46] Only very recently, a Ru(II) complex was covalently bound to mesoporous silica nanoparticles (MSN) for a subsequent cellular uptake of the particles and release of the ruthenium complexes to be transformed upon light irradiation into a cytotoxic complex 47 and a similar approach has been studied using other ruthenium complexes 48 or silicon nanoparticles. 49 or other non-polymeric nanoparticles.…”

Section: -29mentioning

confidence: 99%

Mesoporous silica nanoparticles functionalised with a photoactive ruthenium(ii) complex: exploring the formulation of a metal-based photodynamic therapy photosensitiser

et al. 2019

View full text Add to dashboard Cite

A series of nanomaterials based on mesoporous silica have been synthesised and functionalised with a photoactive polypyridyl ruthenium(ii) complex, namely [Ru(bipy)2-dppz-7-hydroxymethyl][PF6]2 (bipy = 2,2'-bipyridine, dppz = dipyrido[3,2-a:2',3'-c]phenazine), by various methods. The functionalisation reactions were based on the covalent binding to different ligands attached to the pores of the mesoporous nanoparticles and a simple physisorption using polyamino-functionalised mesoporous silica nanoparticles. The resulting nanostructured systems have been characterised by XRD, XRF, BET, SEM and TEM, observing the incorporation of the metallodrug onto the nanostructured silica in a different way depending on the synthetic method used in the loading reactions. In our studies, we have also observed that functionalisation with the metallodrug causes changes in the structural and textural features of the materials. The phototherapeutic activity of the ruthenium-functionalised materials in HeLa cervical cancer cells has been tested and the preliminary results are presented herein.

show abstract

Section: -29mentioning

confidence: 99%

Mesoporous silica nanoparticles functionalised with a photoactive ruthenium(ii) complex: exploring the formulation of a metal-based photodynamic therapy photosensitiser

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The FTIR spectra of both BAC and BAC-SiO 2 (Figure 2a) exhibited C-H stretching bands (2854 cm −1 and 2924 cm −1 ) and C-H bending vibration band (1457 cm −1 ), due to alkylammonium groups. 12–14 Asymmetric (1044 cm −1 ) and symmetric (809 cm −1 ) bands associated with Si-O-Si were observed in the spectra of BAC-SiO 2 before and after calcination. 20–21…”

mentioning

confidence: 94%

“…2,9 MSNs demonstrated significant advantages over traditional nano-based formulations for potential treatment of diabetes, inflammation, and especially cancer. 10–14 However, significant effort is still warranted to overcome the key challenges involved with developing effective DDSs that can attain: 1) sufficient drug loading capacity, 2) controlled or activated release, 3) targeted delivery of drug, and 4) biocompatibility.…”

mentioning

confidence: 99%

One-Pot Hydrothermal Synthesis of Benzalkonium-Templated Mesostructured Silica Antibacterial Agents

et al. 2018

View full text Add to dashboard Cite

Novel mesostructured silica microparticles are synthesized, characterized and investigated as a drug delivery system (DDS) for antimicrobial applications. The materials exhibit relatively high density (0.56 g per 1 g SiO2) of BAC, pore channels of 18 Å in width, and high surface area (1500 m2/g). Comparison of SAXRD pattern with BJH pore size distribution data suggests that the 18 Å pores exhibit short range ordering and a wall thickness of ca. 12 Å. Drug release studies demonstrate pH-responsive controlled release of BAC without additional surface modification of the materials. Prolonged drug release data was analyzed using a power law (Korsmeyer-Peppas) model and indicates substantial differences in release mechanism in acidic (pH 4.0, 5.0, 6.5) versus neutral (pH 7.4) solutions. Microbiological assays demonstrate a significant time-dependent reduction in Staphylococcus aureus and Salmonella enterica viability above 10 and 130 mg L−1 of the synthesized materials, respectively. The viability of cells is reduced over time compared to control samples. The findings will help in widening the use of BAC as a disinfectant and bactericidal agent, especially in pharmaceutical and food industries where Gram-positive and Gram-negative bacterial contamination is common.

show abstract

“…This passive targeting approach could be achieved by oil dispersions, loading onto nanoparticles, encapsulation in polymeric particles or liposomes [57][58][59][60][61] , although this concept is currently controversial discussed. 62 As examples, selenium [63][64][65] , silver 66 , gold [67][68][69] and silicon [70][71][72][73][74] nanoparticles as well as upconverting nanoparticles [75][76][77] were successfully loaded with Ru(II) polypyridine complexes, forming a drug delivery vehicle. Further, the physical encapsulation of Ru(II) polypyridine complexes into polymeric partciles [78][79][80][81][82][83][84][85][86] , micelles [87][88][89] , dendrimers 90 or liposomes [91][92] was reported.…”

Section: Introductionmentioning

confidence: 99%

Polymeric Encapsulation of a Ruthenium Polypyridine Complex for Tumor Targeted 1- and 2-Photon Photodynamic Therapy

Karges¹,

Li²,

Zeng³

et al. 2020

Preprint

View full text Add to dashboard Cite

Photodynamic therapy is a medical technique, which is gaining increasing attention to treat various types of cancer. Among the investigated classes of photosensitizers, the use of Ru(II) polypyridine complexes is gaining momentum. However, the currently investigated compounds generally show poor cancer cell selectivity. As a consequence, high drug doses are needed, which can cause side effects. To overcome this limitation, there is a need for the development of a suitable drug delivery system to increase the amount of PS delivered to the tumor. Herein, we report on the encapsulation of a promising Ru(II) polypyridyl complex into polymeric nanoparticles with terminal biotin groups. Thanks to this design, the particles showed much higher selectivity for cancer cells in comparison to non-cancerous cells in a 2D monolayer and 3D multicellular tumor spheroid model. As a highlight, upon intravenous injection of an identical amount of the Ru(II) polypyridine complex, an improved accumulation inside an adenocarcinomic human alveolar basal epithelial tumor of a mouse by a factor of 8.7 compared to the Ru complex itself was determined. The nanoparticles were found to have a high phototoxic effect upon 1-photon (500 nm) or 2-photon (800 nm) excitation with an eradication of an adenocarcinomic human alveolar basal epithelial tumor inside a mouse. Overall, this work describes, to the best of our knowledge, the first <i>in vivo</i> study demonstrating the cancer cell selectivity of a very promising Ru(II)-based PDT photosensitizer encapsulated into polymeric nanoparticles with terminal biotin groups.

show abstract

Mesoporous silica nanoparticles-assisted ruthenium(II) complexes for live cell staining

Cited by 26 publications

References 50 publications

Mesoporous silica nanoparticles functionalised with a photoactive ruthenium(ii) complex: exploring the formulation of a metal-based photodynamic therapy photosensitiser

Mesoporous silica nanoparticles functionalised with a photoactive ruthenium(ii) complex: exploring the formulation of a metal-based photodynamic therapy photosensitiser

One-Pot Hydrothermal Synthesis of Benzalkonium-Templated Mesostructured Silica Antibacterial Agents

Polymeric Encapsulation of a Ruthenium Polypyridine Complex for Tumor Targeted 1- and 2-Photon Photodynamic Therapy

Contact Info

Product

Resources

About